Celltrion is strengthening its presence in the Japanese biosimilar market. The company’s drug Begzelma (active ingredient: bevacizumab), used for treating metastatic colorectal cancer and non-small cell lung cancer, has secured over 60% market share in Japan. With the upcoming launch of Omilclo (active ingredient: omalizumab) in the second half of the year, the expansion of its local portfolio is expected to accelerate.
According to market research firm IQVIA and local data released on May 18, Begzelma achieved a 64% market share (based on prescriptions) in March. This marks a significant increase from 50% in September of the previous year, representing a rise of over 14% in just six months.
Begzelma has successfully overcome its status as a latecomer to become the leading product in Japan, quickly gaining market share since its launch at the end of 2022, surpassing five competing products, including the original.
Celltrion's success in Japan is closely tied to the local healthcare system, where the use of cost-effective biosimilars benefits hospitals, patients, and the government alike. Other key products such as Herzuma, Remsima, and Uplizna are also performing well in the market.
The company’s financial results support this growth. In the first quarter of this year, Celltrion reported record sales of 1.145 trillion won and an operating profit of 321.9 billion won, raising expectations for annual sales to exceed 5 trillion won.
Industry observers are keenly watching whether Celltrion can expand its successful oncology model into autoimmune diseases in Japan. If Omilclo and the future launch of Remsima SC are successful, Japan is likely to become a key growth area for Celltrion.
Celltrion's market influence is expected to grow further. Omilclo, which received product approval from Japan's Ministry of Health, Labour and Welfare (MHLW) in March, is being prepared for launch in the second half of the year. Additionally, the world’s only subcutaneous formulation of infliximab, Remsima SC, is also planned for entry into the Japanese market.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.